I have returned from my visit with Dr. Burger at MD Anderson. There has been a newer drug approved by the FDA called Calquence (Acalabrutinib). This is in the same drug class as Imbruvica, that I’ve previously been on: a BTK inhibitor. It has been reported to have a lower side effect profile than Imbruvica. Since the drug has worked well, and the side effects are what have been the issue, we decided to give this a try. So we will forgo beginning Venetoclax (the next, and only drug option left at this time) and save it in our arsenal.
Dr. Burger said he is not concerned about the amount of CLL in my marrow increasing from 30% (at initial diagnosis April 2016) to 54% (August 2019) because the latter was checked when I had been off Imbruvica and my white count was very high. This can also skew the percentage shown in the marrow. This was beyond relieving to hear.
I was prepared for an insurance battle. Remember it took me (long!!!) 6 weeks, and a couple of appeals, to get Imbruvica initially approved. The sticker shock on these meds is truly mind blowing. But it was approved on the first round! Yay!!
Dr. Burger did not want me to have any off days with Imbruvica, before the switch to Calquence, because of the issues I had last time. So far I’ve only had some migraine-like headaches since the switch. And if that’s the worst of it, I’ll be very pleased. But it’s still early. The constant need for water and thirst is still an issue, but I was prepared for that—as it’s the same type drug. And that’s become my new normal anyway; I can deal with it!
I will get blood work checked in 1 month locally to see how things look. And the main issue will be to watch for a relief from side effects. Only time will tell. I am to go back to Houston in June, unless I need to go back sooner because of side effects.
Thank you for your support! My family and I are very grateful.
